Subject:
- Active Substance: Sofosbuvir
- Name: Epclusa®
- Therapeutic area: Chronic hepatitis C
- Pharmaceutical company: Gilead Sciences GmbH
Time table:
- Start: 15.02.2022
- Final decision by G-BA: 04.08.2022
Final decision:
- No additional benefit proved
Subject:
Time table:
Final decision: